Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/106258
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Non-HDL cholesterol and triglycerides: implications for coronary atheroma progression and clinical events |
Author: | Puri, R. Nissen, S. Shao, M. Elshazly, M. Kataoka, Y. Kapadia, S. Tuzcu, E. Nicholls, S. |
Citation: | Arteriosclerosis, Thrombosis and Vascular Biology, 2016; 36(11):2220-2228 |
Publisher: | Lippincott Williams & Wilkins |
Issue Date: | 2016 |
ISSN: | 1079-5642 1524-4636 |
Statement of Responsibility: | Rishi Puri, Steven E. Nissen, Mingyuan Shao, Mohamed B. Elshazly, Yu Kataoka, Samir R. Kapadia, E. Murat Tuzcu, Stephen J. Nicholls |
Abstract: | Objectives: Non–high-density lipoprotein cholesterol (non-HDLC) levels reflect the full burden of cholesterol transported in atherogenic lipoproteins. Genetic studies suggest a causal association between elevated triglycerides (TGs)-rich lipoproteins and atherosclerosis. We evaluated associations between achieved non-HDLC and TG levels on changes in coronary atheroma volume. Approach and Results: Data were analyzed from 9 clinical trials involving 4957 patients with coronary disease undergoing serial intravascular ultrasonography to assess changes in percent atheroma volume (ΔPAV) and were evaluated against on-treatment non-HDLC and TG levels. The effects of lower (<100 mg/dL) versus higher (≥100 mg/dL) achieved non-HDLC levels and lower (<200 mg/dL) versus higher (≥200 mg/dL) achieved TG levels were evaluated in populations with variable on-treatment low-density lipoprotein cholesterol (LDLC) </≥70 mg/dL and C-reactive protein </≥2 mg/L and in patients with or without diabetes mellitus. On-treatment non-HDLC levels linearly associated with ΔPAV. Overt PAV progression (ΔPAV>0) was associated with achieved TG levels >200 mg/dL, respectively. Lower on-treatment non-HDLC and TG levels associated with significant PAV regression compared with higher non-HDLC and TG levels across all levels of LDLC and C-reactive protein and irrespective of diabetic status (P<0.001 across all comparisons). ΔPAV were more strongly influenced by changes in non-HDLC (β=0.62; P<0.001) compared with changes in LDLC (β=0.51; P<0.001). Kaplan–Meier sensitivity analyses demonstrated significantly greater major adverse cardiovascular event rates in those with higher versus lower non-HDLC and TG levels, with an earlier separation of the non-HDLC compared with the LDLC curve. Conclusions: Achieved non-HDLC levels seem more closely associated with coronary atheroma progression than LDLC. Plaque progression associates with achieved TGs, but only above levels of 200 mg/dL. These observations support a more prominent role for non-HDLC (and possibly TG) lowering in combating residual cardiovascular risk. |
Keywords: | Atherosclerosis; low-density lipoprotein; non-HDL; residual risk; triglycerides |
Rights: | © 2016 American Heart Association, Inc. |
DOI: | 10.1161/ATVBAHA.116.307601 |
Published version: | http://dx.doi.org/10.1161/atvbaha.116.307601 |
Appears in Collections: | Aurora harvest 8 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.